Hallym University Medical Center
Hyo Jung Kim
CASE 1
• 71세 남자로 내원 3개월 전부터 움직이면 더 심해지는 허리의 통증으로 정형외과 및 한방병원에서 척추압박골 절로 치료받던 환자로, 내원 1주전부터 두통과 양안의 시 력저하로 안과 방문하여 망막출혈을 진단받고 혈액종양 내과로 의뢰됨.
Present Illness
• 과거력: 15년 전 appendectomy
• 가족력: 아들이 위암으로 사망
• 음주력: 소주 반병/1개월
• 흡연력: 40PY
• 약물복용력: 없음
Medical History
Physical examination
• 환자는 창백하며 오래 아팠던 것처럼 보이고 허리가 약간 굽은 상태로 의식은 명확함.
• 혈압은 120/70 mmHg, 맥박은 96/분, 호흡수 18/분, 체온 36.8 도, 전신 림프절 종대 없음.
• 흉부 청진에서 호흡음 정상 및 심잡음도 들리지 않았음.
• 복부 진찰에서 촉진되는 장기비대는 없음.
• 흉추하부 및 요추 상부에 압통 있음.
• 양측하지에 1도의 부종이 있음.
Fundoscopic finding
Lab Data
PBS
환자의 증상과 검사소견을 종합하였을 때, 현재 환자에게 가장 응급으로
처치하여야 하는 상황과 그 치료는?
Hyperviscosity syndrome
Plasmapheresis
환자에게 추가적으로 시행하여 진단 및 병기, 예후를 알기 위하여 도움이
되는 검사들은?
PEP IFE
Serum
Urine
M-peak 3.8 g/dL
BM aspiration
Plasma cell 31%
Chromosome study: 46, XY
환자는 MPT 치료를 3주기 시행하고 빈혈이 호전되며 허리의 통증이 많이
호전되었다.
환자의 치료 반응에 대해서 어떻게
평가하겠는가?
환자는 MPT를 7회까지 시행하고 말초신경병 Gr III로 치료를 중단하였다.
이후 8개월간 손발의 통증은 점차 호전되고 있었다.
그러나 1주일전부터 심해지는 등의 통증과 더불어 보행의 장애, 내원 3일전부터 배변장애로 외래를 내원하였다.
신체검진에서 하지근력이 감소하였고, 감각장애가 있었다.
이 환자에서 바로 시행하여야 하는 검사 및 처치는?
Sarah Newbury, the first reported patient with multiple myeloma.
Blood2008
CLASSIFICATION OF PLASMA CELL PROLIFERATIVE DISORDERS
I. Monoclonal gammopathies of undetermined significance (MGUS) A. Benign (IgG, IgA, IgD, IgM, and rarely, free light chains)
B. Associated neoplasms or other diseases not known to produce monoclonal proteins C. Biclonal gammopathies
D. Idiopathic Bence Jones proteinuria II. Malignant monoclonal gammopathies
A. Multiple myeloma (IgG, IgA, IgD, IgE, and free light chains) 1. Overt multiple myeloma
2. Smoldering multiple myeloma 3. Plasma cell leukemia
4. Nonsecretory myeloma 5. IgD myeloma
6. Osteosclerotic myeloma (POEMS syndrome) 7. Solitary plasmacytoma of bone
8. Extramedullary plasmacytoma B. Waldenström's macroglobulinemia
1. Other lymphoproliferative diseases III. Heavy chain diseases (HCDs)
A. γ-HCD B. α-HCD
C.μ -HCD
IV. Cryoglobulinemia
V. Primary amyloidosis (AL)
Multiple Myeloma
Clonal proliferation of malignant plasma cells
Overall incidence 5/100,000 but much higher in the elderly
Median age ~ 65years
Genetic component recently recognized
Blood 2011;635-637
Multiple myeloma
key features of biology-1
All patients progress through an MGUS phase
Myeloma is not one disease 2
At least 7 subtypes based on cytogenetic and molecular features
Highest risk cytogenetic subtypes by FISH▪ t(4;14), - del 17p
▪ t(14;16), - abnormalities of chromosome 1
End stage disease may be characterized by
Extramedullary disease
Loss of monoclonal proteinInt J cancer 2009;125;2417-2150, Int J Hematol 2013;97;313-323
Multiple myeloma
key features of biology-2
Pathophysiology depends on interaction with marrow microenvironment
Progression is not linear process - concept of
“Darwinian evolution and tiding clones”
Blood. 2012;120;1067-76 Harrison’s Principles of Internal Medicine, 17th Ed,
Multiple myeloma
Diagnosis based on finding over 10% plasma cells in bone marrow
In most cased, plasma cells make a monoclonal immunoglobulin protein
“CRAB”= symptomatic myeloma requiring treatment
Anemia-Hb <10g/dL (or 2 g/dL below normal)
Bone lesions
Creatinine > 176 umol/L (2mg/dL)
Hypercalcemia > 2.8 mmol/L (11.5mg/dL)Diagnostic criteria for MGUS, asymptomatic myeloma and symptomatic myeloma (adapted from IMWG 2003).
MGUS Asymptomatic myeloma Symptomatic myeloma M-protein in serum <30 g/l
Bone marrow clonal plasma cells <10% and low level of plasma cell infiltration in a trephine biopsy (if done) No related organ or tissue
impairment (no end organ damage including bone lesions)
M-protein in serum
‡30 g/l and/or Bone marrow clonal plasma cells
‡10%
No related organ or tissue impairment (no end organ damage including bone lesions) or symptoms
M-protein in serum and/or urine* Bone marrow (clonal) plasma cells
 or biopsy proven plasmacytoma
Myeloma-related organ or tissue impairment (including bone lesions)
*No specific concentration required for diagnosis. A small percentage of patients have no detectable M-protein in serum or urine but do have myeloma-related organ impairment (ROTI) and increased bone marrow plasma cells (non- secretory myeloma). If flow cytometry is performed, most plasma cells (‡90%) will show a ‘neoplastic’ phenotype.
Some patients may have no symptoms but have related organ or tissue impairment.
Myeloma-related organ or tissue impairment (ROTI)
Clinical effects due to
myeloma Definition
*Increased calcium levels
*Renal insufficiency *Anaemia
*Bone lesions
Other
• Corrected serum calcium >0.25 mmol/l above the upper limit of normal or >2.75 mmol/l
• Creatinine >173 lmol/l
• Haemoglobin 2 g/dl below the lower limit of normal or haemoglobin
<10 g/dl
• Lytic lesions or osteoporosis with compression fractures (MRI or CT may clarify)
• Symptomatic hyperviscosity, amyloidosis, recurrent bacterial infections (>2 episodes in 12 months)
MRI, Magnetic resonance imaging; CT, Computerized tomography.
*CRAB (calcium, renal insufficiency, anaemia or bone lesions).
IMWG 2003
Guidelines for standard investigative workup: diagnosis
Dimopoulos MA, et al for the international myeloma workshop
History and physical examination :
Pain, comorbidities, amyloid symptoms
Blood counts & chemistry :
Hb, cytopenia, calcium and creatinine, B2MG, LDH
Protein : Serum & 24h Urine :
electrophoresis, immunofixation + lgs quantitation, Measurement of
serum free light chains*
Radiological skeletal bone survey
Bone Marrow aspirate and/or biopsy: Morphology, Cytogenetics (FISH)FLC : mandatory in non-secretory, oligosecretory: BJ escape & Risk of progression in MGUS and SMM
not replace 24h urine, Measurement of urine-free light chain levels or urine total , and total levels is not
recommended
M/75 with chest wall pain
CASE2
When to repeat special tests:
follow-up or at relapse
Do not repeat skeletal survey unless bone symptoms
BM aspirate & / or biopsy if:
Suspicion of oligosecretory myeloma progression
When myelodysplastic syndrome is considered (presence of cytopenias)
New clinical trial
FISH analyses only if :
Standard-risk FISH at diagnosis
Equivocal tests
Anemia in a “low tumor MM”
Exclude other causes of anemia
Mild hypercalcemia without bone lesions
Exclude primary hyperparathyroidism
Lytic lesions with <10% PC and small MC
Exclude metastatic carcinoma with MGUS
ADVANCES !! : sensitive tests for diagnosis, prognosis and to monitor treatment efficacy
Outside BM
Heavy-light chain
CT & PET
At BM level
Molecular cytogenetics
Flow cytometry
Molecular biology
▪ ASO-PCR
▪ Next generation sequencing
Can we improve the measurement of involved an uninvolved immunoglobulins?
The novel Hevylite TM assay enables to accurately measure each isotype-specific heavy and light chain (HLC) (i.e., lgGκ, lgGλ, IgAκ, lgAλ, lgMk, and lgMλ)
Specific measurement of the monoclonal (intact) lg
Measures isotype-specific suppression of the uninvolved HLC-pair to test the impact of immune paresis
HLC-pair suppression is a risk factor for progression of MGUS
HLC rations after treatment correlate with survival in symptomatic multiple
myeloma
Innovations to evaluate the disease outside the BM: Bone Disease
imaging techniques : skeletal survey
80% of patients with MM will have radiological evidence of skeletal lesion (can’t be substituted by MRI or CT)
Disadvantages: Low sensitivity, low specify
Only demonstrate lyric disease when at least 30% of bone substance has been lostBlood 2011;635-637
Rx
(AP & L) Skull
(AP & L) Cervical spine (AP & L) Thoracic spine (AP & L) Lumbar spine
(AP & L) Femurs (AP & L) Humerus
(PA) Chest (ribs and scapula)
(PA) Pelvis
Magnetic resonance imaging (MRI)
Mandatory
Presumed diagnosis of solitary plasmacytoma Detailed evaluation of a painful skeletal area
Suspicion of cord compression
Pre-kyphoplasty
Recommended
Smoldering (asymptomatic) myeloma Vertebral collapse in the contract of osteoporosis
Non secretory myeloma
Consider
Screening of spine or pelvic plasmacytomas in symptomatic MM Identification of diffuse pattern (prognosis)
Other imaging techniques
CT scan When MRI unavailable or contraindicated (metal devices)
Bone pain without lytic lesions
To clarify lytic lesions ribs, sternum & scapulae
To clarify the extent of soft tissues & risk of fracture
To plan radiotherapy or surgery PET-scan Not recommended for routine use
Selected cases:
• Suspected extramedullary disease
• Evaluations of rib bone lesions
• High LDH
• Bence Jones scape
• Rapidly recurrent disease
Staging systems for Multiple Myeloma
Combinations for Induction in Myeloma
IMWG uniform Response criteria (I)
Response
sub-category Response criteria
Stringent complete response (sCR)
Complete
response (CR)*
Very good partial response (VGPR)*
Partial response (PR)*
Stable disease (SD)
CR as defined below plus
• Normal SFLC ratio
• Absence of phenotypically aberrant plasma cells by multiparameter flow cytometry
• Negative immunofixation on the serum and urine and
• Disappearance of any soft tissue plasmacytomas and
• <5% bone marrow plasma cells
• Serum and urine M-protein detectable by immunofixation but not on electrophoresis or
• 90% reduction in serum M-protein plus reduction in 24-h urinary M-protein by 90% or to <100 mg/24 h
• 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by 90% or to <200 mg/24 h
• Not meeting criteria for CR, VGPR, PR or progressive disease
* In patients with light-chain only and non-secretory myeloma, it is recommended that the SFLC assay is used to assess response. It is recognised that a proportion of patients have a low level M-protein in the serum and/or urine and in these patients the SFLC assay should be considered for the assessment of response and subsequent progression.
It should be noted that monitoring of response to therapy should be carried out by the same test, using the same test platform and laboratory to optimise monitoring. When SFLC assay is used to monitor disease response, the response criteria are as follows: CR is defined by negative immunofixation and a normal SFLC ratio, VGPR is defined by 90% decrease in the difference between the involved and uninvolved free light chain concentrations and PR by a 50% decrease in the difference between involved and uninvolved SFLC levels. If SFLC assay is also uninformative, PR is defined by >50% reduction in BM plasma cells provided baseline BM plasma cell percentage was 30%, and if present at baseline, a 50% reduction in the size of soft tissue plasmacytomas.
Durie et al 2006, Rajkumar et al, 2011
Relapse subcategory Relapse criteria Progressive
disease (PD)
Requires at least one of the following:
• 25% increase in serum M-protein (absolute increase must be ‡5 g/l)
• 25% increase in urine M-protein (absolute increase must be ‡200 mg/24 h)
• 25% increase in the difference between involved and uninvolved SFLC levels (used in patient s with light-chain, non-secretory and oligo-secretory disease) (absolute increase must be >10 0 mg/l)
• 25% increase in bone marrow plasma cell percentage (absolute percentage must be ‡10%)
• Development of new bone lesions or soft tissue plasmacytoma
• Development of hypercalcaemia
Clinical relapse Requires at least one of the following:
• Development of new bone lesions or soft tissue plasmacytoma
• Increase in size of existing plasmacytomas or bone lesions
• Any of the following attributable to myeloma:
Development of hypercalcaemia
Development of anaemia (drop in Hb ‡2 g/dl) Rise in serum creatinine
Relapse from CR Requires at least one of the following:
• Reappearance of serum or urine M-protein by immunofixation or electrophoresis
• Development of >5% plasma cells in the bone marrow
• Appearance of any other sign of progression (e.g. new plasmacytoma, new lytic bone lesion)
IMWG uniform Response criteria (II)
Voting (1)
Which of the following changes, detectable by FISH cytogenetics, is associated with a
better outcome in multiple myeloma patients?
1. del 17p
2. t(14; 16)
3. t(4;14)
4. Hyperdiploidy with trisomies of odd numbered chromosomes
5. Abnormalities of chromosome 1, including
amplification of 1q and/or deletion of 1p
Timeline depicting the history and treatment of multiple myeloma from 1844 to the present.
Blood 2008;111:2962-72
Overall survival from diagnosis of MM
Blood 2008;111:2516-20 1.0
0.8
0.6
0.4
0.2
0.0
Proportion surviving
A
1.00.8
0.6
0.4
0.2
0.0
Survival
B
P<0.001 Diagnosis after 1996
Diagnosis during before 1996
0 20 40 60 80 100 120 140 Time from diagnosis (months)
0 20 40 60 80 100 120 140 Time
1977-82 1983-88 1989-94 1994-00 2001-06
NEJM 2011;164: 1046-1060
Suggested Treatment for newly diagnosed MM
Transplantation-eligible patient Transplantation-ineligible patient
Three-drug induction Two-drug induction Three-drug induction Two-drug induction
Veldex +cyclophosphamide or doxorubicin
or lenalidomide
or thalidomide for 3-6 cycle
Veldex for 3-6 cycels or Rd for 4 cycles
MPT for 6-12 cycles or MPB for 9 cycles or MPR for 9 cycles followed by maintenance with R until progression or intolerance
Veldex for 8 cycles or Rd until progression or intolerance
Maintenance with thalidomide or lenalidomide until progression or intolerance
Autologous stem-cell transplantation
Patient with newly diagnosed multiple myeloma
Induction Therapy for
Transplantation Candidate
• To induce high remission rates rapidly
• With minimal toxicity
• To preserve haemopoietic stem cell
function
ASCT in Myeloma
- Where we were ……
Induction High-dose
melphalan + ASCT
Stem cell mobilization /collection
VAD
Dexamethasone alone
Dexamethasone + thalidomide
Outcomes
Overall response rate CR/nCR rate
80%
20%
Median PFS 20-28mos
Median overall survival 48-68mos
Response Before ASCT Is An Important Predictor of Outcome in MM
• Retrospective analysis (n=1567)
→ Patient who achieved CR or VGPR before undergoing an auto-HCT had significantly longer TTP, PFS and OS after the transplant.
(importance of effective anti-myeloma therapy to maximize the response before proceeding to auto-HCT)
ASH 2011(Abstract 4119), poster presentation
PFS OS
Importance of achieving CR post-transplant
• Retrospective analysis (n=126)
→ Achievement of CR post-ASCT is the only important prognostic regardless of response following induction
ASH 2011(Abstract 2018), poster presentation
CR following HDM + ASCT
<CR following HDM + ASCT
p=0.002
Phase III trials of novel induction regimens before ASCT
Study /Author N Induction regimen #ASCT Consoli-
dation Maintenance HOVON-50
Lokhost1 536 TAD
VAD 1 -
- Thal
INF-a MRC IX
Morgan2 1144 CTD
CVAD 1 -
- Thal
- IFM2005-02
Harousseau3 482 BD
VAD 1 or 2 +/- len +/- len
in some HOVON 65/GMMG-HD
Sonneveld4 613 PAD
VAD 1 or 2 -
- B 1.3mg/m2
Thal 50mg/d GIMEMA MMY-3006
Cavo5 474 VTD
Thal+dexa 2 VTD
Thal+dex Dex
Dex PETHEMA/GEM
Rosinol6 306 Thal+dexa
VBMCP/VBAD/Vel VTD 1 -
-
IFN-a2b Thal Thal + B IFM 2007-02
Moreau7 199 BD
vTD 1 or 2 NA NA
1. Lohorst HM et al. Blood.2010;115:1113-20 2. Morgan GJ et al. Blood . 2012;119:7-15 3. Harousseau JL et al. J Clin Oncol. 2010;28:4621-9 4. Sonneveld P et al. Blood 2010;116;40[abstract]
5. Cavo M et al. Lancet 2010;376:2075-85 6. Rosinol L et al. Hematologica 2011;96:69[Abstract]
7. Moreau P et al. Blood 2011;118:5752-8
Post-induction Results in Phase III trials
Study Induction regimen
Post-Induction Post-ASCT
Median (mos) PFS
Median (mos) OS
3 yr (%) OS ORR (%) ≥VGP
R (%) CR/
nCR(%) ORR
(%) ≥VGPR
(%) CR/
nCR(%)
HOVON-50 TAD
VAD 71
57 37
18 3
2 84
76 54
44 14
12 34
25 73
60 -
-
MRC IX CTD
CVAD 82
71 33
27 13
8 91
90 84
62 50
37 27
25 NYR
63 -
-
IFM2005-02 BD
VAD 78
63 38
15 15
6 80
77 54
37 35
18 36
30 -
- 81%
77%
HOVON 65/GMMG- HD
VAD PAD 83
59 42
11 15
5 -
- 61
36 30
15 34
24 -
- 78%
71%
GIMEMA
MMY-3006 VTD
Thal+dexa 93
79 62
28 31
11 93
84 62
58 31
11 3yr:68%
3yr:56% -
- 86%
84%
PETHEMA/G
EM VTD
Thal+dexa VBMCP/VBAD/Vel
82 64 75
60 29 38
35 14 22
77 58 73
60 29 36
46 24 38
NYR 27 38
- - -
80% 80%
80%
IFM 2007-02 vTD
BD 88
81 49
36 31
22 89
86 58
74 61
52 26
30 -
- -
-
Comparison of side effects related to myeloma treatment with novel agents.
Thalidomide Bortezomib Lenalidomide
Neutropenia No No Yes
Thrombocytopenia No Yes Yes
Neuropathy Yes Yes No
Constipation Yes Low risk Low risk
Diarrhoea No Yes No
Somnolence Yes No No
Fatigue Yes Yes Yes
Thrombotic risk Yes No Yes
Route of administration Oral Intravenous Oral
Modern components of ASCT
Considerations in interpreting phase III studies
Timing of randomization may affect result
most include novel agents before and after ASCT
Induction High-dose
therapy + ASCT CONSOLIDATION MAINTENANCE THERAPY
Potential integrations of novel agents
Stem cell mobilization
/collection
Jan Waldenström
(courtesy of Giampaolo
Merlini, Pavia, Italy)
Induction Therapy for
Transplantation Non-candidate
• To achieve the maximum durable response
• With minimal treatment related
toxicity
Important aim of treatment:
Achievement of high-quality, sustained
CR balanced with acceptable toxicity
• Retrospective analysis: 3 randomized European trials of GIMEMA and HOVON groups (N=1175)
• First-line treatment
MP (n=332), MPT (n=332), VMP (n=257), VMPT-VT (n=254)
•Significant benefit also seen when analysis is restricted to patients >75 years old
Hematologic CR correlates with long-term PFS and OS in elderly patients treated with novel agents
Gay et al. Blood 2011; 117(11):3025-31
PFS OS
P <0.001 P <0.001
CR
VGPR PR
CR
VGPR PR
Pr ob abili ty Pr ob abili ty
60 50
40 30
20 10
0 100
80
60
40
20
0
Months
P =0.001
PFS
Immunophenotypic CR 90% at 3y
“ Stringent CR” 38% at 3y Conventional CR 57% at 3y PR (≥70% reduction) 28% at 3y
Paiva et al; J Clin Oncol. 2011;29(12):1627-33.
The better the quality of the response the longer the
survival (Immunophenotypic CR): GEM2005>65y
Comorbidity Is a Key Factor in Survival
Charlson et al. J Chronic Dis. 1987;40:373.
Age-Comorbidity
Score N Actual 10-Year
Survival (%)
0-1 369 97-99
2 136 87
3 109 79
4 42 47
5 29 34
Summary of randomized trials
MPT vs MP as induction in elderly patients.
Study Regimen n CR (%) >PR (%) Median PFS Median OS (months) (months) IFM 99-06
(Facon et al, 2007)
MPT vs. MP vs.
MEL100* 125 13 76 27.5 51.6
196 2 35 17.8 33.2
126 18 65 19.4 38.3
IFM 01-01
(Hulin et al, 2009)
MPT vs. MP 113 7 61 24.1 45.3
116 1 31 19 27.7
(Gulbrandsen et al, 2008) MPT vs. MP 357 6 42 16 29
evaluable 3** 28 14 33
HOVON 49 study
(Wijermans et al, 2008)
MPT vs. MP 165 2 66 13 37
168 2 47 9 30
GIMEMA
(Palumbo et al, 2006), MPT vs. MP 129 15.5 76 21.8 45.0 updated in
(Palumbo et al, 2008a) 126 2 48 14.5 47.6
(n)CR, (near) complete response; PR, partial response; MPT, melphalan, prednisolone, thalidomide; MP, melphalan, prednisolone;
MEL100, melphalan 100 mg/m2.
*This study involved a 3-way randomization, including an arm consisting of standard induction followed by intermediate dose melphalan and stem cell rescue.
**CR/nCR only reported.
VISTA Study: VMP vs MP
Overall survival Time to next therapy
JCO 2010;28:2259-66
Best Overall Response Overall Survival
Lenalidomide + high dose vs low dose Dexa
Lancet Oncol 2010;11:29-37
High dose
(n=214) Low dose
(n=208) Total
(n=422) P value
Overall response rate 81 70 76 0.009
CR + VGPR 50 40 45 0.040
CR 5 4 50 -
Immunofixation(-) CR 13 10 11 -
VGPR 33 26 30 -
PR 31 30 30 -
MR 5 13 9 -
No response/SD 4 8 6 -
PD 4 2 3 -
unevaluable 6 7 6 -
Data are number(%),
*Odds ration for differnce in response 1-85(80% CI 1.37-2.49)
Once-weekly administration of bortezomib as a strategy to improve tolerability
Study details Grade ¾
GI toxicity Grade 3/4 peripheral neuropathy
Discontinuation due to AE
VISTA: VMP1-3
Bortezomib
twice-weekly
20% 14% 34%(GIMEMA)4
Bortezomib once-weekly
- 5% 17%
(PETHEMA/GEM)5
Bortezomib
once-weekly
7% 7% 12%††Discontinuations due to SAEs 1. San Miguel et al. NEJM 2008;359:906
2. San Miguel et al. NEJM 2008;359:906; Supplementary Appendix 3. Mateos et al. J Clin Oncol 2010;28:2259-66
4. Palumbo et al. JCO 2010; 28:5101-09 5. Mateos et al. Lancet Oncol 2010;11:934-41
Study details CR+PR CR PFS 3 yrs-OS VISTA: VMP
1-3Bortezomib twice-weekly 71% 30% TTP:24 m 68%
Modified VISTA
4(GIMEMA) Bortezomib once-weekly VMPTVT
VMP
90% 81% 42%
24% 37 m
27 m 85%
80%
Modified VISTA
5(PETHEMA) Bortezomib once-weekly
VMP vs VTPVT vs VP 80% 23%42% 31 m 70%
Once-weekly administration of bortezomib as a strategy to maintain/improve the efficacy
1. San Miguel et al. NEJM 2008;359:906
2. San Miguel et al. NEJM 2008;359:906; Supplementary Appendix 3. Mateos et al. J Clin Oncol 2010;28:2259-66
4. Palumbo et al. J Clin Oncol 2010;28:5101-9 5. Mateos et al. Lancet Oncol 2010;11:934-41
Once-weekly administration of bortezomib as a strategy to improve tolerability
Study details Planned
bortezomib dose Delivered bortezomib dose
VISTA: VMP
1Bortezomib twice-weekly 67.6 mg/m
238.5 mg/m
2Modified VISTA
2Bortezomib once-weekly (GIMEMA)
46.8 mg/m
239.4 mg/m
2Modified VISTA
3Bortezomib once-weekly
(PETHEMA/GEM) 36.4 mg/m
232.9 mg/m
2Mateos et al. IMW 2011: abstract 175
Bortezomib IV versus SC
222 relapsed and/or refractory MM patients. Bz is given at conventional dose and scheme
Moreau et al. Lancet Oncology 2011; 12(5): 431-40 Arnulf B et al. Haematologica 2012: Epub ahead of print
Bortezomib IV (n=73) Bortezomib SC (n=145) Primary endpoint: response after 4/8cycles
(single agent bortezomib or +/-dex))
ORR 42%/52% 42%/52%
CR 8%/12% 6%/10%
TTP 9·4 m 10·4 m
Bortezomib IV Bortezomib SC
All grades Grade ≥3 All grades Grade ≥3
Periph Neurop 53% 16% 38% 6%
P=0·04 and 0·03
No diferences in pharmakokinetics studies
Voting (2)
Which of the following regimens, which include an
immunomodulatory derivative, has been shown to produce better progression-free and/or overall survival in phase III trials when
compared to melphalan and prednisone alone (MP) in elderly
myeloma patients not eligible of autologous stem cell transplantation?
1. Thalidomide + dexamethasone
2. Melphalan + prednisone + pomalidomide
3. Lenalidomide + dexamethasone
4. Melphalan + prednisone + thalidomide
5. Carfilzomib+ dexamethasone
Henry Bence Jones.
Blood2008
High Dose Therapy
ASCT vs AlloSCT
Summary of randomized controlled trials
Conventional chemotherapy vs HDT & ASCT.
Trial n EFS
(median, months) OS
(median, months) References IFM90
Conventional 100 8% at 7 years 25% at 7 years Attal et al (1996) SCT 100 16% at 7 years 43% at 7 years Harousseau et al (2005) MRC Myeloma VII
Conventional 200 32 20 Child et al (2003)
SCT 201 54 months 42
MAG91
Conventional 91 13 64 Fermand et al (1998)
SCT 94 39 65
PETHEMA
Conventional 83 34 67 Blade et al (2001)
SCT 81 43 67
EFS, event-free survival; OS, overall survival; SCT stem cell transplantation.
ASCT for ≥ 70 years
Age
Am J hematol 2008;83:614-7
Time to progression Overall Survival
No Maintenance 28-day courses until relapse
Lenalidomide: 10 mg/day, D1-21
Secondary Randomization
Two courses
Melphalan: 200 mg/m
2, D-2 Stem cell support: D0
• Primary endpoints: PFS, RR, DoR
• Secondary endpoint: OS Six 28-day courses
Melphalan: 0.18 mg/kg/day, D1-4 Prednisone: 2 mg/kg/day, D1-4 Lenalidomide: 10 mg/day, D1-21
Primary Randomization Four 28-day courses
Lenalidomide: 25 mg/day, D1-21
(low dose) Dexamethasone: 40 mg/day, D1, 8, 15, 22
Stratified by ISS & age
Phase III: MPR versus tandem ASCT
ASH 2011 (Abstract 3069), poster presentation
Timing of ASCT
• Median follow up 26 months
MPR (n=202) MEL 200 (n=200) p
CR 20% 25% 0.49
≥VGPR 60% 58% 0.24
2-year PFS 54% 73% <0.001
2-year OS 87% 90% 0.19
Standard-risk patients
2-year PFS 46% 78% 0.007
High-risk patients
2-year PFS 27% 71% 0.004
Patients who achieved CR
2-year PFS 66% 87% <0.001
Patients who achieved PR
2-year PFS 56% 77% <0.001
Gr 3/4 neutropenia 55% 89% <0.001
Gr 3/4 infections 0% 17% <0.001
Gr 3/4 gastrointestinal toxicity 0% 21% <0.001
DVT 2.44% 1.13% 0.43
Second tumors 0.5% 1.5% 0.12
•High risk : t(4;14), t(14;16), del17p ASH 2011 (Abstract 3069), poster presentation
Phase III: MPR versus tandem ASCT
Timing of ASCT
Summary of selected reported series of
Allo-SCT in myeloma.
Conditioning regimen n CR % TRM % EFS (%) OS (%) References
FI AlloSCT
Cyclophosphamide/TBI 39 47.2 31.5 13.3 (5 years) 28.1 (5 years) Hunter et al (2005) Melphalan/TBI 78 54.7 35.3 36.2 (5 years) 44.1 (5 years) Hunter et al (2005)
Bu/Cyclo/TBI 15 53.3 17 31 (6 years) 77 (6 years) Kro¨ger et al (2003)
Cyclo/TBI (+/) Idarubicin) 53 19 34 Median 18 months Median 25 months Lokhorst et al (2003)
Cyclo/TBI 53 22 (7 years) 39 (7 years) Barlogie et al (2006a)
Mel/TBI 72 38 22 31.4 (10 years) 39.9 (10 years) Kuruvilla et al (2007)
RIC AlloSCT
Flu/Bu/ATG 41 24 17 41 (2 years) 62 (2 years) Mohty et al (2004)
Flu/TBI200Gy 52 27 17 29.4(1.5 years) 41 (1.5 years) Gerull et al (2005) ASCT fi Flu/TBI200Gy 16 62 16 36 (3 years) 62 (3 years) Bruno et al (2007)
ASCT fi Flu/Bu 46 33 11 . 57 (2 years) Gahrton et al (2001)
ASCT fi Flu/Mel/ATG 17 73 18 56 (2 years) 74 (2 years) Kro¨ger et al (2002)
ASCT fi TBI200Gy 54 57 7 45 (4 years) 69 (4 years) Maloney et al (2003)
ASCT fi Flu/Bu/ATG 65 62.2 10.9 Median 32 months Median 35 months Garban et al (2006) ASCT fi Flu/Mel/TBI200Gy 45 64 36 13 (3 years) 36 (3 years) Lee et al (2003b)
[Non-relapse/Ref] 12 . . 80 (3 years) 80 (3 years)
FI, full intensity/myeloablative conditioning; RIC, reduced intensity conditioning; TRM, treatment-related mortality; ASCT fi , Planned tandem autologous stem cell transplantation followed by an allogeneic stem cell transplantation; Flu, Fludarabine; TBI200Gy, single fraction total body irradiation; Bu, intravenous busulphan;
Cyclo, cyclophosphamide; ATG, anti-thymocyte globulin; Mel, high dose Melphalan
Maintenance Therapy
Thalidomide Maintenance after ASCT
Study /Author N Thalidomide dose Duration PFS/
EFS OS
IFM99-02
Attal/2006
1597 Thal 200mg (median) vs
Observation Until prog
+ +(Australia)
Spencer/2006
2243 Thal 200mg + PRD vs
PRD 12mos
+ +(Brazil)
Maiolino/2008
3212 Thal 200mg +Dex vs
Dex 12mos
+ NSTotal therapy 2
Barlogie/2006
4668 Thalidomide
- Until prog
+ NS(+ in high-risk)
Hovon-50
5Lokhorst/2010 556 Thal 50mg
- Until prog
+ NSNCIC MY. 10
Stewart/2010
6325 Thal 200mg + PRD vs
Observation 48mos
+ NSMRC IX
5Morgan/2012 492 Thal 100mg vs Observation Until prog
+ NS(- in high-risk)
1. Attalet al. Blood.2006;108:3289-94 2. Spencer A et al. JCO . 2009;27:1788-93 3. Maiolino et al. Blood. 2008;112:3703 4. Barlogie B et al. NEJM 2006;354;1021-1030 5. Lokhost HMet al. Blood 2010;115:1113-1120 6. Stewart AK et al. 2010;116:39[Abstract]
7. Morgan GJ et al. Blood 2012;119:7-15
2011 ASH education program Book 197-204
Lenalidomide and Bortezomib Maintenance after ASCT
Study /Author N maintenance dose Duration PFS/E FS OS
IFM2005-02
Attal/2010
1614 Lenali 10-15mg vs
Placebo Until prog + -
CALGB100104
McCarthy/2010
2568 Lenali 10mg vs Placebo Until prog + +
Hovon-65/GMMG-
HD4 Sonneveld /2010 613 B 1.3mg/m
2every 2 wks
Thal 50mg/d 24mos +(?) +(?)
1. Attal et al. Blood.2010;116:310[Abstract]
2. McCarthy PL et al. Blood. 2010;116:37 [Abstract]
3. Sonneveld P et al. Blood. 2010;116:23
2011 ASH education program Book 197-204
MP vs MPR vs MPR-R (65-75 Yrs)
Palumbo A et al NEJM2012; 366:1759-69
Progression free survival (months) Overall Survival (months)
NEJM 2011;164: 1046-1060
Suggested Treatment for newly diagnosed MM
Transplantation-eligible patient Transplantation-ineligible patient
Three-drug induction Two-drug induction Three-drug induction Two-drug induction
Veldex +cyclophosphamide or doxorubicin
or lenalidomide
or thalidomide for 3-6 cycle
Veldex for 3-6 cycels or Rd for 4 cycles
MPT for 6-12 cycles or MPB for 9 cycles or MPR for 9 cycles followed by maintenance with R until progression or intolerance
Veldex for 8 cycles or Rd until progression or intolerance
Maintenance with thalidomide or lenalidomide until progression or intolerance
Autologous stem-cell transplantation
Patient with newly diagnosed multiple myeloma
Timeline depicting the history and treatment of multiple myeloma from 1844 to the present.
Blood 2008;111:2962-72